Randomised clinical trial: pre-dosing with taribavirin before starting pegylated interferon vs. standard combination regimen in treatment-naïve patients with chronic hepatitis C genotype 1

BACKGROUND: Combination therapy with the ribavirin (RBV) prodrug taribavirin (TBV) and pegylated interferon (PIFN) has produced lower rates of anaemia than with RBV and PIFN. Studies have demonstrated that the sharpest decline in viral load during TBV therapy occurs at Weeks 4 through 6, when TBV re...

Descripción completa

Detalles Bibliográficos
Autores principales: Palmer, M, Rubin, R, Rustgi, V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2012
Materias:
Randomised Clinical Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492905/
https://www.ncbi.nlm.nih.gov/pubmed/22708649
http://dx.doi.org/10.1111/j.1365-2036.2012.05188.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492905/
https://www.ncbi.nlm.nih.gov/pubmed/22708649
http://dx.doi.org/10.1111/j.1365-2036.2012.05188.x

Ejemplares similares